TopoGEN, Inc.

Innovative Reagents and Kits for Topoisomerase Research and Mechanism-based Drug Development

Cat.#:	Description:	Size:
Assay Kits: For assaying Topo I, II or Gyrase using your extracts. These kits contain DNA substrates and detailed instruction manual.		
1001-1	Topo II Assay Kit	100 assays
1001-2	Topo II Assay Kit	250 assay
1003	DNA Gyrase Assay Kit	100 assays
1015-1	Topo I Assay Kit	100 assays
1015-2	Topo I Assay Kit	250 assays
Drug Screening/Analysis Kits: For characterizing Topo inhibitors		
1009-1	Topo II Drug Kit	100 assays
1009-2	Topo II Drug Kit	250 assays
1010-1	SDS-Ktation Kit	100 assays
1010-2	SDS-K+ Precipitation Kit	250 assays
1018-1	Topo I Drug Kit	100 assays
1018-2	Topo I Drug Kit	250 assays
1025	DNA Intercalator/Unwinding Kit	50 assays
Kits for Assaying Topoisomerase I or II inhibition in any cell		
1021	Topo I In Vivo Link-Kit	>200 assays
1022	Topo II In Vivo Link-Kit	>200 assays
Kits for analysis of Type II Topoisomerase in cells.		
1030	Topo II Immunofluorescence Kit	>50 Analyses
1035	Topo II Immunoprecipitation Kit	>50 Analyses
Enzymes:		
2000H-1	p170 Human Topoisomerase II	200 units
2000H-2	p170 Human Topoisomerase II	500 units
2005H-1	Human Topoisomerase I	500 units
2005H-2	Human Topoisomerase I	750 units
Antibodies and Related Reagents:		
2010-1	Monoclonal AB Human p170	50 units
2011-1	Rabbit AB Human p170 (For Western blotting, I.F. and Imm.precip.)	250 units
2011-2	Purified C-terminal	50 ug
2011-3	Human Topo II (p170) Marker	20 units
2012	Human AB to Human Topo I (Scleroderma antibody)	500 units
2012-2	Rabbit AB to Human Topo I	250 ul
2014	Rabbit AB Yeast Topo II	250 ul
DNA Substrates for Assaying Topoisomerases and Gyrase:		
2013-1	Kinetoplast DNA	25 ug
2013-2	Kinetoplast DNA	50 ug
2013-3	Kinetoplast DNA	250 ug
2017-1	Linear KDNA	10 ug
2020-1	Decatenated KDNA	10 ug
2023-2	pRYG DNA (Topo II Site)	20 ug
2025-1	Relaxed pRYG DNA	10 ug
2028-1	Linear pRYG DNA	10 ug
2030-2	pHOT1 DNA (Topo I Site)	20 ug
2035-1	Relaxed pHOT1 DNA	10 ug
Topo Inhibitors:		
4110	Camptothecin (10 mM)	0.25 ml
4120	Doxorubicin (10 mM)	0.25 ml
4130	Daunomycin (10 mM)	0.25 ml
4140	Etoposide (10 mM)	0.25 ml
4150	m-AMSA (10 mM)	0.25 ml
4160	Genistein (10 mM)	0.25 ml
4170	Ellipticine (10 mM)	0.25 ml

Introducing our latest kit:

Working with Transcription factors or other DNA binding proteins.....
Interested in Purifying Genomic DNA without using Phenol or Proteases?
- ***The new Non-Enzymatic DNA Isolator Kit allows one to isolate DNA from almost any cell source without losing stably attached proteins (topoisomerase complexes, UV cross linked proteins or nuclear matrix/scaffold attached proteins).***
- ***The kit has what you need to recover protein/DNA complexes directly from the cell....including a control to demonstrate that proteins are bound to genomic DNA!***
- ***For More Information ask about:***
  Cat# 1023 The DNA Isolator Kit

ALSO NEW IN 1995:

-EXCEPT ENZYMES, ALL KITS AND REAGENTS ARE NOW SENT AS AMBIENT TEMPERATURE SHIPMENTS (NON-DRY ICE).

-INTERNATIONAL AND DOMESTIC SHIPMENTS ARE MUCH EASIER IN '95!!!

TopoGEN, Inc.
P.O. Box 20607
Columbus, Ohio
USA 43220

Orders: Toll free (USA only) ***800-867-6436 (800-TopoGEN)***
Fax Numbers (USA): ***800-233-8676 (800-Add-Topo)***
International Telephone: ***(614) 451-5810***
International Fax Line: ***(614) 451-5811***

Need to Place an Order After Hours?
Telephone our answering service (open 24 hrs) for ORDERS ONLY: Tel: 800-837-7911 or (614) 265-9385
Orders may be mailed, called-in or sent by Fax. Domestic Shipments are sent out within 24 hrs. International Shipments are sent out on Mondays.

ANNOUNCEMENT

FY 95 Department of Defense
BREAST CANCER RESEARCH PROGRAM

The U. S. Army will provide $150 million to continue the Department of Defense's Breast Cancer Research Program. Of these monies, $20 million will be allocated for mammography efforts and $15 million will be provided for 3 institutions with dedicated breast cancer centers as described in the 1994 Defense Appropriations Act. The remaining $115 million is designated to initiate new breast cancer research under a solicitation by the Department of the Army.

The U. S. Army Medical Research and Materiel Command (USAMRMC) plans to solicit proposals for breast cancer research for its FY95 Breast Cancer Research Program through a Broad Agency Announcement (BAA) to be released in June 1995. This program will closely follow the strategy outlined by the Institute of Medicine (IOM) in its report to the U. S. Army in 1993. Overall goals of the program include the reduction of the incidence of breast cancer, the increase in survival rates, and the improvement of the quality of life for women diagnosed with this disease. The program will continue to emphasize research that is innovative, interdisciplinary, and complementary to other nationally sponsored efforts. Awards will be made based on scientific excellence and programmatic relevance. Proposals will be sought across **all disciplines** to include the following areas: public health, nonconventional therapies, psychosocial issues, occupational health, nursing research, economics, social sciences, quality of care, epidemiology, and environmental concerns. Proposal submission is targeted for September 1995.

The USAMRMC particularly wants to solicit participation by women, minority individuals and institutions, younger scientists, and scientists not previously involved in breast cancer research.

For more information and/or to request a BAA, please address inquiries to:

COMMANDER, USAMRMC
MCMR-PLF (ATTN: BAA-BC)
Fort Detrick, Maryland 21702-5012
Phone #: (301) 619-7076 or (301) 619-7786
FAX #: (301) 619-7792

VECTOR INFOPAGE™

Essentials for Immunohistochemistry

Counterstains

Hematoxylin — Based on Gill's formula, our hematoxylin is a progressive stain, free of mercury or alcohol and especially designed for immunohistochemical applications.
Cat. No. H-3401 • 500 ml

Methyl Green — Our improved formula provides nuclear staining with a simple protocol. This light green counterstain is ideal for black and white photography and for single or multiple labeling procedures.
Cat. No. H-3402 • 500 ml

Nuclear Fast Red — An easy to use counterstain for blue, brown or black enzyme reaction products.
Cat. No. H-3403 • 500 ml

Antigen Unmasking Solution

This citric acid-based formula was developed to reveal antigens in formalin-fixed, paraffin-embedded tissue sections using high temperature treatment procedures. Provided as 100x stock.
Cat. No. H-3300 • 250 ml

VECTABOND™ Reagent

This tissue section adhesive has become the standard for use in bonding tissue sections to glass slides. Employed for routine paraffin or frozen sections or for antigen unmasking or *in situ* hybridization procedures using high temperature, this reagent avoids problems associated with glue or denatured protein adhesives. Provided as a 50x stock sufficient for treating about 500 slides.
Cat. No. SP-1800 • 7 ml

VECTOR LABORATORIES, INC.
30 Ingold Road
Burlingame CA 94010
(415) 697-3600 Fax: (415) 697-0339

VECTOR LABORATORIES, LTD.
16 Wulfric Square, Bretton,
Peterborough PE3 8RF U.K.
(01733) 265530 Fax: (01733) 263048

plus over 25 distributors worldwide

© 1995 Vector Laboratories, Inc.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 10,000 scientists and physicians involved in cancer research. Members in the AACR enjoy

- subscriptions to the journals *Cancer Research, Cell Growth & Differentiation (CG&D), Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at reduced member rates
- early notification of and reduced registration rates at the AACR Annual Meeting and Special Conferences
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- **Mentorship Program**
- **Travel Awards to Scientific Meetings**

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313

THURSDAY AND FRIDAY, NOVEMBER 16–17, 1995

LYMPHOMA '95: ADVANCES & CONTROVERSIES

Sponsored by the Memorial Hospital Alumni Society
at Memorial Sloan-Kettering Cancer Center
1275 York Ave., New York, NY, 10021

For information contact:

Jean Campbell

Phone: 212-639-3511
Fax: 212-639-3535

ANNOUNCING CLINICAL TRIALS FOR MYELOID LEUKEMIAS:

To determine the safety and efficacy of "antisense" oligodeoxynucleotide therapeutics.

ENTRY CRITERIA INCLUDE:

- *Chronic Myelogenous Leukemia-Chronic Phase*
- *Chronic Myelogenous Leukemia-Blast Crisis*
- *Refractory Acute Myeloid Leukemia*

For information regarding eligibility contact:

ALAN M. GEWIRTZ, M.D. 215-898-4499
SELINA LUGER, M.D. 215-662-7909
EDWARD STADTMAUER, M.D. 215-662-7910

BONE MARROW TRANSPLANT / LEUKEMIA SERVICE • HEMATOLOGY / ONCOLOGY DIVISION
UNIVERSITY OF PENNSYLVANIA MEDICAL CENTER

THE OHIO STATE UNIVERSITY

INTERNAL MEDICINE/MEDICAL ONCOLOGY

Postdoctoral Fellowships in Oncology are available for those with M.D., D. O., M.D./Ph.D., or Ph.D. degrees who are U.S. citizens or U.S. permanent residents. Unique research training by interdisciplinary faculty with research interests including clinical research, developmental therapeutics, biological response modifiers, pharmacology and pharmacokinetics, hormones and cancer, cancer immunology, molecular biology, and cancer control and prevention. Program prepares trainees for careers in academic or research setting focused on oncology. To receive application, contact:

Stanley P. Balcerzak, M.D.
The Ohio State University
N1025 Doan Hall
410 West Tenth Avenue
Columbus, Ohio 43210

An Equal Opportunity/Affirmative Action Program. Minority applicants are encouraged. Women, minorities, Vietnam-era veterans, disabled veterans, and individuals with disabilities are encouraged to apply.

The Departments of Surgical Oncology and Immunology at The University of Texas M. D. Anderson Cancer Center, Houston, Texas are seeking an investigator to conduct research in molecular tumor immunology. We are interested in an individual with a Ph.D. or M.D./Ph.D. background for a joint appointment in the tenure track at the assistant, associate, or full professor level. This investigator will help nurture programs involving cancer vaccine development strategies and investigations into the relationship of HLA polymorphism as a predictor of cancer risk and will also be expected to develop and maintain an independent research program.

This appointment rank, salary and benefits will be commensurate with training and experience. The position includes eligibility for appointment at The University of Texas Health Science Center at Houston Graduate School of the Biological Sciences with access to graduate student trainees. Women and minority applicants are particularly encouraged to apply. If interested, please send a curriculum vitae, summary of research background and future directions with three letters of recommendation to:

Raphael E. Pollock, M.D., Ph.D.
Associate Professor and Chairman
UT M. D. Anderson Cancer Center
Department of Surgical Oncology, Box 106
1515 Holcombe Boulevard
Houston, Texas 77030

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER •
- STAGE II OR LOCALLY ADVANCED BREAST CANCER •
- METASTATIC COLORECTAL CANCER TO THE LIVER •
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER •
- MESOTHELIOMA, PULMONARY METASTASES, STAGE III A, B LUNG CANCER OR ESOPHAGEAL CANCER •
- LOCALIZED SOFT TISSUE SARCOMAS •
- PERITONEAL CARCINOMATOSIS •

CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.
FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL (301)496-1533.

NATIONAL CANCER INSTITUTE

A Public Service Announcement Courtesy of this Publication

For Research Use Only

Anti-

MBL

EPITOPE TAGGING

Polyclonal Antibodies

Anti-HA-tag

Code No. 561 561-5
Quantity 100µg 500µg

Immunogen YPYDVPDYA (HA-tag) - KLH
Host Rabbit
Specificity This antibody recognizes Ha-tag
Presentation IgG fraction from antisera by ammonium sulfate precipitation.
Lyophilized form.
Reconstitution ; reconstitute with 100µl of distilled water.
Application This antibody can be used for immunoblotting and immunofluorescence.
Immunoblotting ; 10µg/ml
Immunofluorescence ; 10µg/ml



Anti-Myc-tag

Code No. 562 562-5
Quantity 100µg 500µg

Immunogen EQKLISEEDL(Myc-tag) - KLH
Host Rabbit
Specificity This antibody recognizes Myc-tag
Presentation IgG fraction from antisera by ammonium sulfate precipitation.
Lyophilized form.
Reconstitution ; reconstitute with 100µl of distilled water.
Application This antibody can be used for immunoblotting and immunofluorescence.
Immunoblotting ; 10µg/ml
Immunofluorescence ; 10µg/ml



Anti-VSV-G tag

Code No. 563 563-5
Quantity 100µg 500µg

Immunogen YTDIEMNRLGK(VSV-G tag) - KLH
Host Rabbit
Specificity This antibody recognizes VSV-G tag
Presentation IgG fraction from antisera by ammonium sulfate precipitation.
Lyophilized form.
Reconstitution ; reconstitute with 100µl of distilled water.
Application The antibody can be used for immnoblotting and immunofluorescence.
Immunoblotting ; 10µg/ml
Immunofluorescence ; 10µg/ml



MBL International Corporation
440 Arsenal Street, Watertown, MA 02172, USA
TEL: (617) 926-6964 FAX: (617) 926-6954

MBL
MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
5-10 Marunouchi 3 chome, Naka-ku, Nagoya 460, JAPAN
TEL : (052) 971-2081 FAX : (052) 971-2337